Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction.
This study examined the safety and efficacy of gamma vinyl-GABA (GVG, vigabatrin) for the treatment of methamphetamine and/or cocaine addiction. A total of 30 subjects, who met DSM-IV criteria for methamphetamine and/or cocaine dependence, were enrolled in an open label 9-week safety study. The protocol was specifically designed to include extensive visual field monitoring as well as outcome measures of therapeutic efficacy. Patients were screened twice weekly for the presence of urinary cocaine, methamphetamine, heroin, alcohol, and marijuana. In total, 18/30 subjects completed the study and 16/18 tested negative for methamphetamine and cocaine during the last 6 weeks of the trial. GVG did not produce any visual field defects or alterations in visual acuity. Furthermore, it did not produce changes in vital signs even with continued use of methamphetamine and cocaine. Thus, under conditions that appear to be appropriate for the successful treatment of methamphetamine and/or cocaine addiction, GVG is safe.
Brodie
Jonathan D
JD
Department of Psychiatry, NYU School of Medicine, New York, New York 10016, USA. brodij01@gcrc.med.nyu.edu
Figueroa
Emilia
E
Laska
Eugene M
EM
Dewey
Stephen L
SL
D019970:Cocaine-Related Disorders / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008694:Methamphetamine; D019966:Substance-Related Disorders / Q000188:drug therapy*; D016896:Treatment Outcome; D020888:Vigabatrin / Q000009:adverse effects / Q000627:therapeutic use*
D004791:Enzyme Inhibitors; D008694:Methamphetamine; D020888:Vigabatrin